Mylan Stretches Game Clock, Adds To Costs For Perrigo Takeover Play
This article was originally published in The Tan Sheet
Executive Summary
Perrigo says Mylan shows “desperation” in targeting approval by 50% of its shareholders rather than the 80% approval it initially stated in its regulatory filing. A 50% threshold means Mylan would pay more in interest to lenders because it would be required to continue its takeover attempt longer than initially planned.
You may also be interested in...
Perrigo Gains 180-Day Exclusivity With ANDA Approval For Omeprazole Magnesium PPI
Perrigo receives approval for its ANDA for a Prilosec OTC equivalent and another for a generic of Advil Fast Relief. The firm includes those products in its outlook for $1 billion in new product sales over three years.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.